31st August 2015 – Brussels
The Riga Roadmap sets out an Action Plan for EU and National Policy Makers to Deliver Sustainable, Equitable and Participatory European Health Systems

June 17th, 2015 – by Duane Schulthess
While progress is often slow and laborious when trying to gain traction for new ideas in the ‘Brussels Bubble’, there was much to be optimistic about in the Medicine’s Adaptive Pathways to Patients (MAPPs) meeting held on Thursday June 4 in Luxembourg. Organised as part of EFPIA’s general assembly, a broad cross section of stakeholders attended the MAPPs session to hear what had been accomplished over the last twelve months and discover how the initiative is being moved forward in partnership with the second Innovative Medicines Initiative (IMI2) and the European Medicine’s Agency (EMA).

May 29th, 2015 - by Vital TransformationHealthcare consultancy Vital Transformation is expanding to the United States with the addition of a new partner to head its operations in Washington D.C. Joseph P. Hammang, Ph.D., will join the Vital Transformation team, overseeing the company’s work in the U.S. and supporting its growing presence in Europe.

May 20th, 2015 – by Nuala MoranReal world evidence holds the potential to both increase efficiency in R&D and to bridge the gap between the proof of efficacy required to pass regulatory scrutiny and the demonstration of likely effectiveness needed to satisfy health technology assessment bodies, says Professor Sarah Garner, Associate Director for Science Policy and Research at NICE.

April 24th, 2015 – by Gary Finnegan Reinventing how medicines come to market demands new thinking from regulators, payors, patients and industry, says Professor Luca Pani, Director General of the Italian Medicines Agency. A full transcript of the interview can be downloaded via the link at the end of the article.

Arpil 21st, 2015 - by Alison Kilian On 15 April, thought leaders met in Lyon, France to take part in a panel discussion and Q&A on the potential of advanced therapies and the challenges we face in implementing them in Europe. The event marked the launch of the EBE and Vital Transformation report, “Europe’s Emerging Science: Putting Advanced Therapies into Practice to Deliver Better Health”, a guide to advanced therapies.

Feb 6th, 2015 - by Magda Chlebus While Europe is leading in the development of tools and methodologies in Medicine’s Adaptive Pathways (MAPPs) through the EMA live pilots and upcoming projects in IMI2, the key bottlenecks still holding back its implementation in Europe are gaining traction with the United States congress. This situation illustrates our need in Europe to move quickly and develop implementation strategies and foster political support for MAPPs whilst we still hold the drive and initiative.

Jan 15th, 2015 A new culture is needed to promote the equitable and open sharing of data, to advance science, whilst protecting the interests of all stakeholders, says the US Institute of Medicine The sharing of clinical trials data is clearly in the public interest, but huge effort is required to develop the policies and put in place the technical infrastructure and create a culture of openness, according to a new report from the US Institute of Medicine (IOM).

Dec 12th, 2014 - by Nuala MoranIn a ground-breaking collaboration, The UK’s Digital Catapult, The Fellowship of Post Graduate Medicine, IDEALondon, and Vital Transformation brought together the best and brightest minds in Europe working at the frontiers of research where Personalised Medicines and Health Technologies intersect. This round table demonstrated how next-generation technologies and social media will integrate with public health, thus facilitating the burgeoning market for personalised medicines. The sessions included disruptive start-ups and technology savvy practitioners finding common ground in the desire to bring stratified medicines to patients.